Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - April 20, 2026 289 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMN24 IsKia study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Bjorn Saven: “By supporting early career researchers to do their jobs... November 19, 2021 Resilience Isn’t About Bouncing Back March 8, 2021 FDA Approves HPV Tests That Allow for Self-Collection in a Health... July 24, 2024 Researchers Turn On PTEN Tumor-Suppressor Protein in Cancer Cells June 14, 2019 Load more HOT NEWS As Use of Genomic Data Expands in Cancer Care, Patients Share... Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with... Darolutamide Maintenance Improves Outcomes in Patients with mCRPC Who Were Previously...
